The re-expressed KANK1 by 5-aza-CdR treatment can reduce cell proliferation and increase apoptosis33, suggesting KANK1 might be an option for MPNST therapeutics. This evidence concerns the gene KANK1 and malignant peripheral nerve sheath tumor.